Systematic review: Bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 7, 2015, Pages 802-817

  Pavlidis, P ^a   Powell, N ^b   Vincent, R P ^a   Ehrlich, D ^b   Bjarnason, I ^a   Hayee, B ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; COLESTYRAMINE; INDOMETACIN; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN D;

ARTICLE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; CROHN DISEASE; ENTEROHEPATIC CIRCULATION; ENTEROPATHY; EPITHELIUM; HOMEOSTASIS; HUMAN; ILEUM DYSFUNCTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INTESTINE EPITHELIUM; MICROBIOME; NONHUMAN; NSAID ENTEROPATHY; NSAID INDUCED ENTEROPATHY; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; WESTERN DIET; ANIMAL; COLITIS, ULCERATIVE; ILEUM; IMMUNOLOGY; INTESTINE FLORA; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BILE ACIDS AND SALTS; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL MICROBIOME; HUMANS; ILEUM; INTESTINAL MUCOSA;

EID: 84940787936     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13333     Document Type: Article

References (176)

1. Hofmann AF, Hagey LR,. Bile acid chemistry, biology, and therapeutics during the last 80 years: historical aspects. J. Lipid Res. 2014; 55: 1553-95.
2. Russell DW,. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 2009; 50 (Suppl.): S120-5.
3. Hofmann AF,. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab Rev 2004 Oct; 36: 703-22.
4. Wang Y-M, Ong SS, Chai SC, et al,. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol 2012 Jul; 8: 803-17.
5. Makishima M, Okamoto AY, Repa JJ, et al,. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.
6. Parks DJ, Blanchard SG, Bledsoe RK, et al,. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-8.
7. Jones SA,. Physiology of FGF15/19. Adv Exp Med Biol 2012; 728: 171-82.
8. Ridlon JM, Kang D-J, Hylemon PB,. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-59.
9. Sayin SI, Wahlström A, Felin J, et al,. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17: 225-35.
10. Hofmann AF,. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 2009; 49: 1403-18.
11. Ridlon JM, Kang DJ, Hylemon PB, et al,. Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014; 30: 332-8.
12. Hofmann AF,. The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy. Gastroenterology 1967; 52: 752-7.
13. Walters JRF, Tasleem AM, Omer OS, et al,. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7: 1189-94.
14. Meihoff WE, Kern F,. Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea. J Clin Invest 1968; 47: 261-7.
15. Vantrappen G, Ghoos Y, Rutgeerts P, et al,. Bile acid studies in uncomplicated Crohn's disease. Gut 1977; 18: 730-5.
16. Nishida T, Miwa H, Yamamoto M, et al,. Bile acid absorption kinetics in Crohn's disease on elemental diet after oral administration of a stable-isotope tracer with chenodeoxycholic-11, 12-d2 acid. Gut 1982; 23: 751-7.
17. Nyhlin H, Merrick MV, Eastwood MA, et al,. Evaluation of ileal function using 23-selena-25-homotaurocholate, a-gamma-labeled conjugated bile acid. Initial clinical assessment. Gastroenterology 1983; 84: 63-8.
18. Nyhlin H, Merrick MV, Eastwood MA,. Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT. Gut 1994; 35: 90-3.
19. Konno Y, Hiwatashi N, Kumagai Y, et al,. Studies on biliary and fecal bile acids in Crohn's disease (The 1st report)-Comparison of non-resected cases and resected ones. Nihon Shokakibyo Gakkai Zasshi 1985; 82: 2742-51.
20. Chen F, Ma L, Sartor RB, et al,. Inflammatory-mediated repression of the rat ileal sodium-dependent bile acid transporter by c-fos nuclear translocation. Gastroenterology 2002; 123: 2005-16.
21. Neimark E, Chen F, Li X, et al,. c-Fos is a critical mediator of inammatory-mediated repression of the apical sodium-dependent bile acid transporter. Gastroenterology 2006; 131: 554-67.
22. Rutgeerts P, Ghoos Y, Vantrappen G,. Bile acid studies in patients with Crohn's colitis. Gut 1979; 20: 1072-7.
23. Lapidus A, Einarsson K,. Effects of ileal resection on biliary lipids and bile acid composition in patients with Crohn's disease. Gut 1991; 32: 1488-91.
24. Pereira SP, Bain IM, Kumar D, et al,. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Aliment Pharmacol Ther 2003; 17: 923-33.
25. Cummings JH, James WP, Wiggins HS,. Role of the colon in ileal-resection diarrhoea. Lancet 1973; 1: 344-7.
26. Rutgeerts P, Ghoos Y, Vantrappen G,. Kinetics of primary bile acids in patients with non-operated Crohn's disease. Eur J Clin Invest 1982; 12: 135-43.
27. Chen Y, Ogundare M, Williams CM, et al,. Shotgun cholanomics of ileal fluid. Biochimie 2013; 95: 461-3.
28. Suchy FS, Balistreri WF,. Ileal dysfunction in Crohn's disease assessed by the postprandial serum bile acid response. Gut 1981; 22: 948-52.
29. Heuman R, Sjödahl R, Tobiasson P, et al,. Postprandial serum bile acids in resected and non-resected patients with Crohn's disease. Scand J Gastroenterol 1982; 17: 137-40.
30. Linnet K, Mertz Nielsen A,. Fasting and postprandial serum concentrations of glycine- and taurine-conjugated bile acids in Crohn's disease. Scand J Gastroenterol 1983; 18: 433-8.
31. Bain IM, Mostafa AB, Harding LK, et al,. Bile acid absorption from ileoanal pouches using enema scintigraphy. Br J Surg 1995; 82: 614-7.
32. Johnson MW, Das P, Dewar DH, et al,. Medical management of patients with ileal pouch anal anastomosis after restorative procto-colectomy. Eur J Gastroenterol Hepatol 2009; 21: 9-17.
33. Tan HT, Morton D, Bain IM, et al,. Ursodeoxycholic acid has no influence on function after restorative proctocolectomy in ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1593-6.
34. Konno Y, Hiwatashi N, Kumagai Y, et al,. Studies on biliary and fecal bile acids in Crohn's disease (the 2nd report)-The effect of ED treatment on bile acid metabolism. Nihon Shokakibyo Gakkai Zasshi. 1985; 12: 2889-95.
35. Gnewuch C, Liebisch G, Langmann T, et al,. Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. WJG 2009; 15: 3134-41.
36. Duboc H, Rajca S, Rainteau D, et al,. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013; 62: 531-9.
37. Helander HF, Fandriks L,. Surface area of the digestive tract-revisited. Scand J Gastroenterol 2014; 49: 681-9.
38. Bjarnason I, Takeuchi K, Bjarnason A, et al,. The G.U.T. of gut. Scand J Gastroenterol 2004; 39: 807-15.
39. Odenwald MA, Turner JR,. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. Elsevier Inc 2013; 11: 1075-83.
40. Davenport HW,. Destruction of the gastric mucosal barrier by detergents and urea. Gastroenterology 1968; 54: 175-81.
41. Kirk RM,. Experimental gastric ulcers in the rat: the separate and combined effects of vagotomy and bile-duct implantation into the stomach. Br J Surg 1970; 57: 521-4.
42. Black RB, Hole D, Rhodes J,. Bile damage to the gastric mucosal barrier: the influence of pH and bile acid concentration. Gastroenterology 1971; 61: 178-84.
43. Black RB, Rhodes J, Davies GT, et al,. A controlled clinical trial of cholestyramine in the treatment of gastric ulcer. Gastroenterology 1971; 61: 821-5.
44. Eastwood GL,. Failure of cholestyramine to prevent bile-salt injury to mouse gastric-mucosa. Gastroenterology 1975; 68: 1466-72.
45. Schindlbeck NE, Heinrich C, Stellaard F, et al,. Healthy controls have as much bile reflux as gastric ulcer patients. Gut 1987; 28: 1577-83.
46. Hofmann AF, Hagey LR,. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008; 65: 2461-83.
47. O'Connor CJ, Wallace RG, Iwamoto K, et al,. Bile salt damage of egg phosphatidylcholine liposomes. Biochim Biophys Acta 1985; 817: 95-102.
48. Schölmerich J, Becher MS, Schmidt K, et al,. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties-studies on isolated hepatocytes and lipid membrane vesicles. Hepatology 1984; 4: 661-6.
49. Araki Y, Fujiyama Y, Andoh A, et al,. Hydrophilic and hydrophobic bile acids exhibit different cytotoxicities through cytolysis, interleukin-8 synthesis and apoptosis in the intestinal epithelial cell lines. IEC-6 and Caco-2 cells. Scand J Gastroenterol 2001; 36: 533-9.
50. Faust RG, Wu SL,. The effect of bile salts on oxygen consumption, oxidative phosphorylation and ATP-ase activity of mucosal homogenates from rat jejunum and ileum. J Cell Physiol 1966; 67: 149-57.
51. Zhao DL, Hirst BH,. Bile salt-induced increases in duodenal brush-border membrane proton permeability, fluidity, and fragility. Dig Dis Sci 1990; 35: 589-95.
52. Zhao DL, Hirst BH,. Comparison of bile salt perturbation of duodenal and jejunal isolated brush-border membranes. Digestion 1990; 47: 200-7.
53. Merrett MN, Owen RW, Jewell DP,. Ileal pouch dialysate is cytotoxic to epithelial cell lines, but not to CaCo-2 monolayers. Eur J Gastroenterol Hepatol 1997; 9: 1219-26.
54. Fasano A, Budillon G, Guandalini S, et al,. Bile acids reversible effects on small intestinal permeability. An in vitro study in the rabbit. Dig Dis Sci 1990; 35: 801-8.
55. Raimondi F, Santoro P, Barone MV, et al,. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol 2008; 294: G906-13.
56. Lugo-Martínez V-H, Petit CS, Fouquet S, et al,. Epidermal growth factor receptor is involved in enterocyte anoikis through the dismantling of E-cadherin-mediated junctions. Am J Physiol Gastrointest Liver Physiol 2009; 296: G235-44.
57. Sinha A, Nightingale J, West KP, et al,. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349: 350-7.
58. Powell AA, LaRue JM, Batta AK, et al,. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem J 2001; 356 (Pt 2): 481-6.
59. Shekels LL, Beste JE, Ho SB,. Tauroursodeoxycholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acids. J Lab Clin Med 1996; 127: 57-66.
60. Kakiyama G, Pandak WM, Gillevet PM, et al,. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58: 949-55.
61. Kakiyama G, Hylemon PB, Zhou H, et al,. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am J Physiol Gastrointest Liver Physiol 2014; 306: G929-37.
62. Momozawa Y, Deffontaine V, Louis E, et al,. Characterization of bacteria in biopsies of colon and stools by high throughput sequencing of the V2 region of bacterial 16S rRNA gene in human. Falciani F, editor. PLoS ONE 2011; 6: e16952.
63. Gevers D, Kugathasan S, Denson LA, et al,. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014; 15: 382-92.
64. Frank DN, Robertson CE, Hamm CM, et al,. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 179-84.
65. Morgan XC, Tickle TL, Sokol H, et al,. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13: R79.
66. Atarashi K, Tanoue T, Oshima K, et al,. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2014; 500: 232-6.
67. Llopis M, Antolin M, Carol M, et al,. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm Bowel Dis 2009; 15: 275-83.
68. Darfeuille-Michaud A, Boudeau J, Bulois P, et al,. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-21.
69. Glasser AL, Boudeau J, Barnich N, et al,. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001; 69: 5529-37.
70. Meconi S, Vercellone A, Levillain F, et al,. Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. Cell Microbiol 2007; 9: 1252-61.
71. Hase K, Kawano K, Nochi T, et al,. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009; 462: 226-30.
72. Fujimura Y, Kamoi R, Iida M,. Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. Gut 1996; 38: 724-32.
73. Chassaing B, Rolhion N, de Vallée A, et al,. Crohn disease-associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest 2011; 121: 966-75.
74. Prorok-Hamon M, Friswell MK, Alswied A, et al,. Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut 2014; 63: 761-70.
75. Chassaing B, Etienne-Mesmin L, Bonnet R, et al,. Bile salts induce long polar fimbriae expression favouring Crohn's disease-associated adherent-invasive Escherichia coli interaction with Peyer's patches. Environ Microbiol 2013; 15: 355-71.
76. Münch A, Soderholm JD, Öst Å, et al,. Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission. Aliment Pharmacol Ther 2011; 33: 954-60.
77. Münch A, Ström M, Söderholm JD,. Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. Scand J Gastroenterol 2007; 42: 1167-74.
78. Devkota S, Wang Y, Musch MW, et al,. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012; 487: 104-8.
79. Bjarnason I, Zanelli G, Smith T, et al,. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987; 93: 480-9.
80. Bjarnason I, Peters TJ,. Intestinal permeability, non-steroidal anti-inflammatory drug enteropathy and inflammatory bowel disease: an overview. Gut 1989; 30: 22-8.
81. Elson CO, Sartor RB, Tennyson GS, et al,. Experimental-models of inflammatory bowel-disease. Gastroenterology 1995; 109: 1344-67.
82. Somasundaram S, Rafi S, Hayllar J, et al,. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997; 41: 344-53.
83. Sigthorsson G, Simpson RJ, Walley M, et al,. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002; 122: 1913-23.
84. Somasundaram S, Hayllar H, Rafi S, et al,. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30: 289-99.
85. Beck WS, Schneider HT, Dietzel K, et al,. Gastrointestinal ulcerations induced by anti-inflammatory drugs in rats. Physicochemical and biochemical factors involved. Arch Toxicol 1990; 64: 210-7.
86. Duggan DE, Hooke KF, Noll RM, et al,. Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol 1975; 24: 1749-54.
87. Brodie DA, Cook PG, Bauer BJ, et al,. Indomethacin-induced intestinal lesions in the rat. Toxicol Appl Pharmacol 1970; 17: 615-24.
88. Wax J, Clinger WA, Varner P, et al,. Relationship of enterohepatic cycle to ulcerogenesis in rat small bowel with flufenamic acid. Gastroenterology 1970; 58: 772-80.
89. Satoh H, Guth PH, Grossman MI,. Role of food in gastrointestinal ulceration produced by indomethacin in the rat. Gastroenterology 1982; 83 (1 Pt 2): 210-5.
90. Rainsford KD, Bjarnason I,. NSAIDs: take with food or after fasting? J Pharm Pharmacol 2012; 64: 465-9.
91. Zhou Y, Dial EJ, Doyen R, et al,. Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol 2010; 298: G722-31.
92. Bernardes-Silva CF, Damião AOMC, Sipahi AM, et al,. Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress. Dig Dis Sci 2004; 49: 1569-74.
93. Uchida A, Yamada T, Hayakawa T, et al,. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol 1997; 272 (5 Pt 1): G1249-57.
94. Seitz S, Boelsterli UA,. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 1998; 115: 1476-82.
95. Kent TH, Cardelli RM, Stamler FW,. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 1969; 54: 237-49.
96. Uejima M, Kinouchi T, Kataoka K, et al,. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol 1996; 40: 553-60.
97. Bjarnason I, Hayllar J, Smethurst P, et al,. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992; 33: 1204-8.
98. Taylor NS, Bartlett JG,. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980; 141: 92-7.
99. Bailey ME,. Endotoxin, bile-salts and renal-function in obstructive-jaundice. Br J Surg 1976; 63: 774-8.
100. Wilkinson SP, Moodie H, Stamatakis JD, et al,. Endotoxaemia and renal failure in cirrhosis and obstructive jaundice. Br Med J 1976; 2: 1415-8.
101. Kocsar LT, Bertok L, Varteres V,. Effect of bile acids on intestinal absorption of endotoxin in rats. J Bacteriol 1969; 100: 220-7.
102. Rudbach JA, Anacker RL, Haskins WT, et al,. Physical aspects of reversible inactivation of endotoxin. Ann N Y Acad Sci 1966; 133: 629-43.
103. Pain JA, Bailey ME,. Prevention of endotoxaemia in obstructive jaundice-a comparative study of bile salts. HPB Surg 1988; 1: 21-7.
104. Pain JA, Cahill CJ, Gilbert JM, et al,. Prevention of postoperative renal dysfunction in patients with obstructive jaundice: a multicentre study of bile salts and lactulose. Br J Surg 1991; 78: 467-9.
105. Floch MH, Gershengoren W, Elliott S, et al,. Bile acid inhibition of the intestinal microflora-a function for simple bile acids? Gastroenterology 1971; 61: 228-33.
106. Williams RC, Showalter R, Kern F,. In vivo effect of bile salts and cholestyramine on intestinal anaerobic bacteria. Gastroenterology 1975; 69: 483-91.
107. Inagaki T, Moschetta A, Lee Y-K, et al,. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006; 103: 3920-5.
108. Wilson KH, Kennedy MJ, Fekety FR,. Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium-difficile. J Clin Microbiol 1982; 15: 443-6.
109. Sorg JA, Sonenshein AL,. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008; 190: 2505-12.
110. Rupnik M, Wilcox MH, Gerding DN,. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
111. Sorg JA, Sonenshein AL,. Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol 2009; 191: 1115-7.
112. Buffie CG, Bucci V, Stein RR, et al,. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517: 205-8.
113. Shekels LL, Lyftogt CT, Ho SB,. Bile acid-induced alterations of mucin production in differentiated human colon cancer cell lines. Int J Biochem Cell Biol 1996; 28: 193-201.
114. Strauch ED, Yamaguchi J, Bass BL, et al,. Bile salts regulate intestinal epithelial cell migration by nuclear factor-κB-induced expression of transforming growth factor-β. J Am Coll Surg 2003; 197: 974-84.
115. Riegler FM, Consentini EP,. Bile salts affect epithelial restitution. J Am Coll Surg 2004; 198: 855.
116. Martinez JD, Stratagoules ED, LaRue JM, et al,. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998; 31: 111-8.
117. Yamaguchi J, Toledo A, Bass BL, et al,. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery 2004; 135: 215-21.
118. Kullmann F, Gross V, Rüschoff J, et al,. Effect of ursodeoxycholic acid on the inflammatory activity of indomethacin-induced intestinal inflammation in rats. Z Gastroenterol 1997; 35: 171-8.
119. Cipriani S, Mencarelli A, Bruno A, et al,. Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. Br J Pharmacol 2013; 168: 225-37.
120. Fiorucci S, Antonelli E, Distrutti E, et al,. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 2005; 129: 1210-24.
121. Fiorucci S, Mencarelli A, Cipriani S, et al,. Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. Br J Pharmacol 2011; 164: 1929-38.
122. Cipriani S, Mencarelli A, Chini MG, et al,. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. Ryffel B, editor. PLoS ONE 2011; 6: e25637.
123. Kong J, Zhang Z, Musch MW, et al,. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008; 294: G208-16.
124. Makishima M, Lu TT, Xie W, et al,. Vitamin D receptor as an intestinal bile acid sensor. Science 2002; 296: 1313-6.
125. Yu S, Bruce D, Froicu M, et al,. Failure of T cell homing, reduced CD4/CD8 alpha alpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci USA 2008; 105: 20834-9.
126. Liu W, Chen Y, Golan MA, et al,. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest 2013; 123: 3983-96.
127. Vavassori P, Mencarelli A, Renga B, et al,. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 2009; 183 (10): 6251-61.
128. Renga B, Mencarelli A, Cipriani S, et al,. The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. Boone DL, editor. PLoS ONE 2013; 8: e54472.
129. Lee J, Mo J-H, Katakura K, et al,. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006; 8: 1327-36.
130. Gadaleta RM, van Erpecum KJ, Oldenburg B, et al,. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011; 60: 463-72.
131. Shah YM, Ma X, Morimura K, et al,. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF- B target gene expression. Am J Physiol Gastrointest Liver Physiol 2006; 292: G1114-22.
132. Terc J, Hansen A, Alston L, et al,. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis. Eur J Pharm Sci 2014; 13: 12-9.
133. Poole DP, Godfrey C, Cattaruzza F, et al,. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 2010; 22: 814-e228.
134. Pols TWH, Nomura M, Harach T, et al,. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011; 14: 747-57.
135. Wang Y-D, Chen W-D, Yu D, et al,. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology 2011; 54: 1421-32.
136. Yoneno K, Hisamatsu T, Shimamura K, et al,. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. Immunology 2013; 139: 19-29.
137. Mosser DM, Edwards JP,. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-69.
138. Haselow K, Bode JG, Wammers M, et al,. Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages. J Leukoc Biol. Society for Leukocyte Biology. 2013; 94: 1253-64.
139. Gadaleta RM, Oldenburg B, Willemsen ECL, et al,. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine. Biochim Biophys Acta 2011; 1812: 851-8.
140. Nijmeijer RM, Gadaleta RM, van Mil SWC, et al,. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. Bereswill S, editor. PLoS ONE 2011; 6: e23745.
141. van Schaik FDM, Gadaleta RM, Schaap FG, et al,. Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis. Makishima M, editor. PLoS ONE 2012; 7: e49706.
142. Zhou X, Cao L, Jiang C, et al,. PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat Commun 2014; 5: 4573.
143. Walters JRF, Johnston IM, Nolan JD, et al,. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015; 41: 54-64.
144. Glas J, Seiderer J, Fischer D, et al,. Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1917-24.
145. Attinkara R, Mwinyi J, Truninger K, et al,. Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Res Notes 2012; 5: 461.
146. Xue L-N, Xu K-Q, Zhang W, et al,. Associations between vitamin D receptor polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis. Inflamm Bowel Dis 2013; 19: 54-60.
147. Jansson J, Willing B, Lucio M, et al,. Metabolomics reveals metabolic biomarkers of Crohn's disease. Bereswill S, editor. PLoS ONE 2009; 4: e6386.
148. Blain A, Cattan S, Beaugerie L, et al,. Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002; 21: 51-7.
149. Long MD, Crandall WV, Leibowitz IH, et al,. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 2162-8.
150. Poullis A, Foster R, Shetty A, et al,. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 279-84.
151. Teixeira TFS, Souza NCS, Chiarello PG, et al,. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr 2012; 31: 735-40.
152. Moreno-Navarrete JM, Sabater M, Ortega F, et al,. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. Federici M, editor. PLoS ONE 2012; 5: e37160.
153. John BJ, Abulafi AM, Poullis A, et al,. Chronic subclinical bowel inflammation may explain increased risk of colorectal cancer in obese people. Gut 2007; 56: 1034-5.
154. Kant P, Fazakerley R, Hull MA,. Faecal calprotectin levels before and after weight loss in obese and overweight subjects. Int J Obes (Lond) 2013; 37: 317-9.
155. Spagnuolo MI, Cicalese MP, Caiazzo MA, et al,. Relationship between severe obesity and gut inflammation in children: what's next? Ital J Pediatr 2010; 36: 66.
156. Kohli R, Bradley D, Setchell KD, et al,. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 2013; 98: E708-12.
157. Werling M, Vincent RP, Cross GF, et al,. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol 2013; 48: 1257-64.
158. Ryan KK, Tremaroli V, Clemmensen C, et al,. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014; 509: 183-8.
159. Khalili H, Ananthakrishnan AN, Konijeti GG, et al,. Measures of obesity and risk of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2015; 21: 361-8.
160. Richman E, Rhodes JM,. Review article: evidence-based dietary advice for patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 1156-71.
161. Chassaing B, Koren O, Goodrich JK, et al,. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015; 519: 92-6.
162. Martinez-Medina M, Denizot J, Dreux N, et al,. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut 2013; 63: 116-24.
163. Joshi D, Bjarnason I, Belgaumkar A, et al,. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int 2013; 33: 53-61.
164. Pavlidis P, Heneghan MA, Hayee B,. Cholestyramine treats primary sclerosing cholangitis associated inflammatory bowel disease. J Crohns Colitis 2015; 9: 210.
165. Trivedi PJ, Chapman RW,. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol 2012; 36: 420-36.
166. Miettinen TA,. The role of bile salts in diarrhoea of patients with ulcerative colitis. Gut 1971; 12: 632-5.
167. Jung D, Fantin AC, Scheurer U, et al,. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 2004; 53: 78-84.
168. Bajor A, Kilander A, Gälman C, et al,. Budesonide treatment is associated with increased bile acid absorption in collagenous colitis. Aliment Pharmacol Ther 2006; 24: 1643-9.
169. Kakiyama G, Muto A, Takei H, et al,. A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS. J Lipid Res 2014; 55: 978-90.
170. Glicksman C, Pournaras DJ, Wright M, et al,. Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem 2010; 47 (Pt 5): 482-4.
171. Schaap FG, Trauner M, Jansen PLM,. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11: 55-67.
172. Cheng J, Shah YM, Gonzalez FJ,. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 2012; 33: 323-30.
173. Duboc H, Taché Y, Hofmann AF,. The bile acid TGR5 membrane receptor: From basic research to clinical application. Dig Liver Dis 2014; 46: 302-12.
174. Cantorna MT, McDaniel K, Bora S, et al,. Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. Exp Biol Med 2014; 239: 1524-30.
175. Strom BL, Soloway RD, Rios-Dalenz J, et al,. Biochemical epidemiology of gallbladder cancer. Hepatology 1996; 23: 1402-11.
176. de Kok TM, van Faassen A, Glinghammar B, et al,. Bile acid concentrations, cytotoxicity, and pH of fecal water from patients with colorectal adenomas. Dig Dis Sci 1999; 44: 2218-25.